Discover Commonwealth Medicine, UMass Medical School's new Asset Verification System, AVS Enhance™, and how it's helping states avoid unnecessary costs while simultaneously improving program integrity.
AVS Enhance™ helped one state avoid $125M in costs.
Our approach to dual eligible data analytics led to MassHealth, the Massachusetts Medicaid program, saving over $68 million through benefits optimization and recovering over $21 million in Medicare premium overpayments.
Learn the actions health plan decision makers should consider while developing a comprehensive managed long-term services and supports program. Make sure individuals receive the right service in the right setting.
This study, conducted by researchers from the Center for Health Policy and Research, evaluates the impact of practice participation in a pediatric patient-centered medical home learning collaborative on preventable emergency department visits among children in MassHealth.
Our researchers performed a retrospective evaluation of the multidisciplinary therapeutic class management workgroup that conducted telephonic prescriber outreach in Massachusetts as part of the Massachusetts Medicaid Pharmacy Program's Pediatric Behavioral Health Medication Initiative. The initiative, aims to prevent concerning
behavioral health medication polypharmacy regimes.
This brief, compiled by experts from our Health Law & Policy team, goes over the basics of MassHealth's introduction of Accountable Care Organizations (ACOs). It includes a brief introduction of what an ACO is, the three distinct types of ACOs, who they serve, the services they provide and how they can improve care and contain costs.
Learn how public retirement systems can ensure accurate, complete, clinically sound Medical Board Reviews for disability determinations. Not taking the right steps during the application evaluation process can lead to mistakes.
Our researchers and pharmacists set out to find out how well Ledipasvir/sofosbuvir worked in treating Hepatitis C virus in a Medicaid population. They found the treatment was largely successful in creating a sustained viral response, which was achieved in 95% of members.
An overview of the managed long-term services and supports (MLTSS) national landscape with a focus on our MLTSS best practice framework and the role of LTSS clinical guidelines in that framework.
In an Op-Ed piece for CommonWealth magazine, Warren J. Ferguson of the Health and Criminal Justice Program provides
real world examples of how methadone has proven its efficacy in other states and why this treatment needs to be offered to all incarcerated persons, including those in Massachusetts, with substance use disorder.
Experts from our Clinical Pharmacy Services unit and the Center for Health Policy Research set out to identify best-practice guidelines healthcare providers could use when prescribing to patients with substance use disorders to ensure regimens are followed safely and judiciously.
A team from our Center for Health Policy and Research dig into data on Social Security Disability Insurance and Supplementary Security Income across the United States. Their findings strongly suggest geographic variation in program participation is most likely a result of socioeconomic differences and disability prevalence.
Optometrists across the country enrolled in the Southern New England Practice Transformation Network have helped 22,765 patients avoid the high costs that come with visits to the Emergency Department when they have eye emergencies.
A case study on MassOptions, a free online and telephonic service that simplifies access to LTSS for the elderly, individuals with disabilities and their caregivers in Massachusetts. MassOptions is supported by the multidisciplinary team of UMass Medical School, UHealthSolutions, the Executive Office of Elder Affairs and Community Partners.
This poster evaluates the costs associated with the administration of select high-cost infused medications in site of care programs in Massachusetts Medicaid populations. Site of care programs help payers save money on specialty drug spend by shifting utilization on high costs infused medications to less costly sites of administration.
This poster gives an overview of pulmonary exacerbation rates pre- and post-initiation of Lumacaftor/Ivacaftor (LUM/IVA) in Massachusetts' Medicaid program. Before this study, there had been no published data evaluating real-world outcomes for Medicaid patients receiving this therapy.
Robert Seifert and a team of researchers examine longitudinal health service utilization for homeless family members before and after entering an emergency shelter.
In an Op-Ed piece for Governing magazine, Robert Seifert and Katharine London from our Health Law & Policy team discuss the challenges policy makers face in navigating the path to single payer health-insurance in the United States, and offer some lessons learned from Vermont and California.
The Charitable Trusts Unit within the New Hampshire Attorney General’s Office retained our Health Law & Policy team to assess the current provision of community benefits by Elliot Health System and Southern New Hampshire Health System, Inc. and the potential effects on cost, quality and access that could arise from these entities’ proposed transaction to join together into a regional health system.
This presentation shares the results of a prescriber outreach program seeking to evaluate awareness of the dangers of co-prescribing opioids with other powerful stimulants.
An outline of the budget impacts of two novel therapies for the treatment of nonalcoholic liver disease on the way to being FDA approved is presented in this poster.